Skip to Main content Skip to Navigation
Journal articles

Maintenance hormonal treatment improves progression free survival after a first line chemotherapy in patients with metastatic breast cancer.

Abstract : The present study was conducted in patients with metastatic breast cancer. Its aim was to identify the factors which influence progression -free survival (PFS) and overall survival (OS) after the first line of chemotherapy in patients with positive tumour hormone receptor status. The patients with early disease progression during first-line chemotherapy were not included. In total, 560 patients who achieved a stable disease or a response to first-line chemotherapy were studied. The factors identified to improve the duration of PFS or OS in multivariate analysis were: number of metastatic sites (p = .01; p = .01), metastatic sites (p = .02; p = .04), Disease free interval (p = .001; p < .0001), previous hormonal therapy (p = .03; p = ns), response to first line chemotherapy (p < .0001; p = 0.0001) and an administration of maintenance hormonal therapy (p < .0001; p = .001). The major impact obtained by maintenance hormonal treatment after first-line chemotherapy in this study seems to indicate that this strategy should be recommended in patients with an ER or PgR positive tumour.
Document type :
Journal articles
Complete list of metadatas

https://www.hal.inserm.fr/inserm-00484215
Contributor : Philippe Saas <>
Submitted on : Tuesday, May 18, 2010 - 10:33:07 AM
Last modification on : Wednesday, September 16, 2020 - 10:43:29 AM

Identifiers

  • HAL Id : inserm-00484215, version 1
  • PUBMED : 18461187

Citation

Armelle Dufresne, Xavier Pivot, Christophe Tournigand, Thomas Facchini, Thierry Alweeg, et al.. Maintenance hormonal treatment improves progression free survival after a first line chemotherapy in patients with metastatic breast cancer.. Int J Med Sci, 2008, 5 (2), pp.100-5. ⟨inserm-00484215⟩

Share

Metrics

Record views

499